Clinical Trial

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This research is being done to test a combination of two drugs, Izalontamab Brengitecan (iza-bren) and Adagrasib, in patients with advanced KRAS G12C-mutant NSCLC that hasn't responded to other treatments. The purpose is to see if this combination works better than existing treatments for people whose cancer keeps growing despite KRAS G12C inhibitors.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-12
Trial Details
NCT Number NCT07382726
Lead Sponsor M.D. Anderson Cancer Center
Conditions Non-small Cell Lung Cancer
Enrollment 18 participants
Start Date 2026-05-15
Primary Completion 2027-12-24 (estimated)
Study Completion 2029-12-24 (estimated)
Updated on ClinicalTrials.gov 2026-08-11